Health & Environmental Research Online (HERO)

Print Feedback Export to File
Book/Book Chapter 
Perfluorohexanoic acid pharmacokinetics in mouse, rat, microminipig, pig, monkey and human 
Buck, R; Gannon, S 
American Chemical Society 
Washington, DC 
Abstracts of Papers of the 253rd National meeting of the American Chemical Society 
Perfluorohexanoic acid (PFHxA) is a perfluorocarboxylic acid (PFCA) that has been widely identified in the aqueous environment. In order to conduct a human health risk characterization, it is necessary to understand both its toxicology and phamacokinetics in mammals. The elimination kinetics of PFHxA have been determined from published data for multiple mammalian species: mouse, rat, microminipig, pig, monkey and human. For each species, the data was compiled and modeled to identify the kinetic profile of elimination from blood including calculation of elimination rate (hr-1) and elimination half-life (hr). The study shows that PFHxA elimination kinetics in mammals is consistent with a rapid initial (alpha) phase followed by a slower terminal (beta) phase. Further, the PFHxA alpha phase elimination has a first-order half-life range of 1-2 hours in mouse, rat, microminipig, pig, monkey and human. The alpha phase elimination in mammals accounts for over 99.7% of the total PFHxA elimination in mammals. PFHx- elimination is extensive in the rapid alpha phase and there are no significant pharmacokinetic differences across mammals: mice, rats, monkeys, pigs and humans. The overall conclusion of this kinetic assessment is that PFHxA does not appear to exhibit significantly different elimination kinetics across a wide range of mammalian species. The results suggest that for human health risk assessment, the interspecies pharmacokinetics adjustment factor applied to a hazard assessment benchmark should be small. Details of the assessment for each species will be presented. 
253rd National Meeting of the American-Chemical-Society (ACS) on Advanced Materials, Technologies, Systems, and Processes 
San Francisco, CA 
April 2-6, 2017 
     Title and Abstract Screening
          Tagged as Supplemental
               ADME TK